FRST

In Q1 2026, the company reported $7.3 million net income available to common shareholders, or $0.30 per diluted share, a decrease from the prior year due to a Panacea investment gain, but operating net income increased to $8.1 million, or $0.33 per diluted share. Margaret Weichert was appointed as a director and a member of the Corporate Governance Committee on June 30, 2026. In Q2 2026, net income available to common shareholders rose to $9.4 million, or $0.38 per diluted share, from $2.4 million in the prior year, bringing the first half 2026 net income to $16.7 million, or $0.68 per diluted share. The company projected a $7 million pretax core conversion lift for 2027, with an estimated $0.22 per share impact. A quarterly dividend of $0.10 per share was declared in August 2026, payable on August 21, 2026. Dr. Allen R. Jones, Jr. resigned as a director on August 31, 2026, reducing the Board size to ten. Shareholders elected ten directors, including new independent board members Scott R. Gamble and J. Brock Saunders, and ratified Crowe, LLP as the independent registered public accounting firm for 2026 at the annual meeting on September 15, 2026. Between September 22, 2025, and September 18, 2026, the share price increased by 49.53%.